SCHEMBL20378249

SCHEMBL20378249

Cc1nc(C2CCC2)oc1C(=O)O

nearest known ligand 0.37

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
GAA P10253 1/20 0.37
HSD17B10 Q99714 1/20 0.37
HCAR2 Q8TDS4 1/20 0.37
ALDH1A1 P00352 3/20 0.34
HPGD P15428 2/20 0.34
TSHR P16473 2/20 0.34
MAPT P10636 2/20 0.34
ADCY1 Q08828 3/20 0.34
NPC1 O15118 3/20 0.33
ATM Q13315 1/20 0.33
NPSR1 Q6W5P4 1/20 0.33
MEN1 O00255 2/20 0.33
KMT2A Q03164 2/20 0.33
HCRTR2 O43614 1/20 0.32
ADCY8 P40145 1/20 0.32
TRPV4 Q9HBA0 1/20 0.32
EPHX2 P34913 2/20 0.31
CYP2C19 P33261 1/20 0.31
LMNA P02545 1/20 0.31
PPARG P37231 1/20 0.31

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL20378281 0.95 ADCY1 (0.39) GAAHSD17B10ALDH1A1HPGDADCY1
SCHEMBL18114139 0.93 MAPT (0.40) GAAHSD17B10HCAR2ALDH1A1HPGD
SCHEMBL8614460 0.81 MAPT (0.36) GAAHCAR2ALDH1A1HPGDTSHR
SCHEMBL3828944 0.81 ADCY1 (0.37) ALDH1A1HPGDTSHRADCY1NPC1
SCHEMBL20378349 0.81 HCRTR2 (0.48) GAAHSD17B10ALDH1A1HPGDTSHR
SCHEMBL20378327 0.80 PIK3CG (0.38) GAAHSD17B10ALDH1A1HPGDTSHR
SCHEMBL3822457 0.79 HCRTR2 (0.34) ALDH1A1HPGDTSHRMAPTHCRTR2
SCHEMBL3530308 0.77 HCRTR2 (0.48) HSD17B10ALDH1A1HPGDTSHRMAPT
SCHEMBL3529338 0.77 HCRTR2 (0.48) HSD17B10ALDH1A1HPGDTSHRMAPT
SCHEMBL20320295 0.75 RAB9A (0.34) ALDH1A1ADCY1NPC1ADCY8LMNA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-10344026-B2 Compositions and methods of targeting mutant K-ras NANTBIO, INC. (US) 2019-07-09 US disclosed
US-10344026-B2 Compositions and methods of targeting mutant K-ras NANTBIO, INC. (US) 2019-07-09 US disclosed
US-20180201610-A1 COMPOSITIONS AND METHODS OF TARGETING MUTANT K-RAS NANTBIO, INC. 2018-07-19 US disclosed
US-20180201610-A1 COMPOSITIONS AND METHODS OF TARGETING MUTANT K-RAS NANTBIO, INC. 2018-07-19 US disclosed
US-20180201610-A1 COMPOSITIONS AND METHODS OF TARGETING MUTANT K-RAS NANTBIO, INC. 2018-07-19 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-10344026-B2 Compositions and methods of targeting mutant K-ras KRAS, NRAS, HRAS GAA 1776/4885HSD17B10 3966/4885HCAR2 4303/4885
US-20180201610-A1 COMPOSITIONS AND METHODS OF TARGETING MUTANT K-RAS KRAS, NRAS, HRAS GAA 1776/4885HSD17B10 3966/4885HCAR2 4303/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.